Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 25 versus ADZENYS ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 25 versus ADZENYS ER.
ADDERALL XR 25 vs ADZENYS ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR is a combination of dextroamphetamine and amphetamine, which are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, resulting in increased synaptic concentrations. This leads to CNS stimulation.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
20-60 mg orally once daily in the morning; starting dose 20 mg, titrate weekly by 10-20 mg based on response and tolerability.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
None Documented
None Documented
Dextroamphetamine: 10-13 hours; levoamphetamine: 11-14 hours. Effective half-life supports once-daily dosing with extended duration.
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Renal: approximately 90% (30-40% unchanged, remainder as metabolites); fecal: minimal (<2%) via biliary elimination.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Category C
Category C
CNS Stimulant
CNS Stimulant